Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
|
|
Zimmer Highlights Vivacit-E? Vitamin E Advanced Bearing Technology at 2013 AAOS Annual Meeting
Publish date: Mar 21, 2013
![]()
PR Newswire CHICAGO, March 21, 2013
CHICAGO, March 21, 2013 /PRNewswire/ -- Zimmer Holdings,
Inc. (NYSE: ZMH; SIX: ZMH), a global leader in musculoskeletal health, is highlighting Vivacit-E® Advanced Bearing
Technology with Vitamin E at the 2013 American Academy of Orthopaedic Surgeons annual meeting. Vivacit-E material
is formulated with antioxidant protection to deliver the longest lasting bearing material for orthopaedic implants. Zimmer's
proprietary manufacturing process results in an advanced highly cross-linked polyethylene material that delivers unmatched
oxidative stability, ultra-low wear rates and exceptional strength. Zimmer first introduced Vivacit-E technology
in hip replacements, and the material is now also available in unicompartmental knee replacements and Persona
TM
The Personalized Knee System.
It is widely understood in orthopaedics that oxidation is a primary cause of articular surface decay, which can increase
wear leading to osteolysis and implant failure. The Vitamin E incorporated in Vivacit-E material is a powerful
antioxidant that quenches harmful free radicals to prevent oxidative material degradation. Vivacit-E technology
prevents oxidative aging through an advanced grafting process that covalently binds the Vitamin E into the polymer chain.
"Vivacit-E technology is the next great material science innovation from Zimmer. This advanced bearing material
is engineered with antioxidant protection for exceptional wear resistance and long-term oxidative stability," said Jeff
McCaulley, President of Zimmer Reconstructive. "With exciting applications already in hips and knees, Vivacit-E
material will become a platform technology across Zimmer's portfolio of products, much like our Trabecular Metal
TM
Technology." In comparative in-vitro wear tests, after 50 million cycles, Vivacit-E hip replacement liners demonstrated a 95%
reduction in wear when compared to conventional polyethylene liners tested to 5 million cycles. In knee replacements,
Vivacit-E material demonstrated a 96% reduction in wear compared to conventional polyethylene when tested to 5 million
cycles. Extensive testing demonstrated Vivacit-E technology also retains its improved tensile strength and does
not elute Vitamin E, unlike first generation Vitamin E materials. After accelerated aging to 16 times longer than the
industry standard, Vivacit-E material maintained its physical properties and oxidative stability. For more information about Vivacit-E Vitamin E Advanced Bearing Technology, visit Zimmer at Booth 529 at the 2013
American Academy of Orthopaedic Surgeons annual meeting in Chicago, or go to www.zimmer.com.
About the Company
Zimmer Safe Harbor Statement SOURCE Zimmer Holdings, Inc.
|
|